News PharmaEngine, Inc.

Equities

4162

TW0004162003

End-of-day quote Taipei Exchange Other stock markets 06:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
90.6 ^TWD	-0.11%		-2.16%	-14.12%

Apr. 24	PharmaEngine, Inc. Announces First Patient Dosed in Phase I Trial of PEP07 for Solid Tumors	CI
Mar. 18	PharmaEngine, Inc. Announces ONIVYDE Obtains TFDA Approval for New Regimen in First-Line Treatment of Metastatic PDAC	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

PharmaEngine, Inc. Announces First Patient Dosed in Phase I Trial of PEP07 for Solid Tumors	Apr. 24	CI
PharmaEngine, Inc. Announces ONIVYDE Obtains TFDA Approval for New Regimen in First-Line Treatment of Metastatic PDAC	Mar. 18	CI
PharmaEngine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 12	CI
PharmaEngine, Inc. Announces Consolidated Revenue Results for the Month and Year Ended December 2023	Feb. 29	CI
PharmaEngine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 06	CI
TFDA Approves PharmaEngine, Inc.'s PEP07 Phase I Clinical Trial for Solid Tumor Cancers	23-09-22	CI
PharmaEngine, Inc. Announces First Patient Dosed in Phase I Trial of Pep07 for Hematological Cancers	23-08-15	CI
PharmaEngine, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-04	CI
PharmaEngine, Inc. Announces Dividend, Payable on September 1, 2023	23-07-27	CI
PharmaEngine, Inc. Announces EMAs Acceptance of Onivyde's Type II Variation Application	23-07-11	CI
PharmaEngine, Inc. Files Post-Approval Change Application for A New Indication of ONIVYDE to TFDA	23-06-21	CI
PharmaEngine, Inc. Announces Approval of Phase 1 Clinical Study of Pep07 by TFDA	23-06-14	CI
PharmaEngine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04	CI
PharmaEngine, Inc. Announces Resignation of Peter Wu as Senior Director of Marketing & Sales	23-04-27	CI
PharmaEngine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-17	CI
Australia HREC Approves and Australia TGA Acknowledges PharmaEngine, Inc.'s Phase 1 Clinical Study of PEP07	23-03-03	CI
PharmaEngine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-04	CI
PharmaEngine, Inc. Announces Change of Board of Directors Chairperson	22-09-01	CI
PharmaEngine, Inc. Announces Management Changes, Effective September 1, 2022	22-08-30	CI
PharmaEngine, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-03	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News PharmaEngine, Inc.

Equities

4162

TW0004162003

Summary

Filters